Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Long-Term Debt Repayments (2016 - 2019)

Fate Therapeutics' Long-Term Debt Repayments history spans 6 years, with the latest figure at $14.0 million for Q4 2019.

  • For Q4 2019, Long-Term Debt Repayments changed N/A year-over-year to $14.0 million; the TTM value through Dec 2019 reached $22.7 million, changed N/A, while the annual FY2019 figure was $15.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $14.0 million in Q4 2019 per FATE's latest filing, up from $6.7 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $14.0 million in Q4 2019 to a low of $600000.0 in Q3 2015.
  • Average Long-Term Debt Repayments over 4 years is $3.7 million, with a median of $2.0 million recorded in 2016.
  • The largest YoY upside for Long-Term Debt Repayments was 253.11% in 2017 against a maximum downside of 5.26% in 2017.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $600000.0 in 2015, then skyrocketed by 229.17% to $2.0 million in 2016, then soared by 239.7% to $6.7 million in 2017, then skyrocketed by 108.67% to $14.0 million in 2019.
  • Per Business Quant, the three most recent readings for FATE's Long-Term Debt Repayments are $14.0 million (Q4 2019), $6.7 million (Q3 2017), and $2.0 million (Q2 2017).